Cosmo Pharmaceuticals NV

COPN

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    332

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.5011.400.12%
CAC 408,347.2011.56-0.14%
DAX 4025,411.446.100.02%
Dow JONES (US)49,309.96280.24-0.57%
FTSE 10010,137.353.35-0.03%
HKSE26,848.47239.990.90%
NASDAQ23,758.9525.050.11%
Nikkei 22553,549.161,609.273.10%
NZX 50 Index13,656.0527.24-0.20%
S&P 5006,971.745.53-0.08%
S&P/ASX 2008,808.5017.200.20%
SSE Composite Index4,138.7626.53-0.64%

Market Movers